

GP/1643  
PT-11



DOCKET NO.: UPAP-0287

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

AUG 31 2001

TECH CENTER 1600/2900

In Re Application of:

Velpandi Ayyavoo et al.

Serial No.: 09/486,625

Group Art Unit: 1643

Filing Date: September 13, 2000

Examiner: Not Yet Assigned

For: **ATTENUATED VIF DNA IMMUNIZATION CASSETTES FOR GENETIC VACCINES**

DATE OF DEPOSIT: 27 AUGUST 2001

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231.

Paul K. Legaard  
TYPED NAME: Paul K. Legaard  
REGISTRATION NO.: 38,534

Assistant Commissioner for Patents  
Washington DC 20231

Dear Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

- ☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first office action after the filing of request for continued examination under §1.114, no additional fee is required.

- ☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐the first or ☐second After Final Submission, therefore:
- ☐ Certification in Accordance with §1.97(e) is attached; or
- ☐ The fee of \$180.00 as set forth in §1.17(p) is attached.
- ☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or before an action that otherwise closes prosecution in the application, therefore:
- ☐ Certification in Accordance with §1.97(e) is attached; or
- ☐ The fee of \$180.00 as set forth in §1.17(p) is attached.
- ☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); and the submission fee of \$180.00 as set forth in §1.17(p).
- ☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
- ☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:
- ☐ In view of the voluminous nature of references **[list as appropriate]**, and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☐ In accordance with §1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35

U.S.C. §120 have been made in the instant application:


- ☐ Copies of references [list as appropriate] listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. , filed .
- ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050.  
This form is submitted in duplicate.

Attached is a copy of the EPO International Search Report dated **July 27, 2001**, which indicates the documents considered to be relevant.

There are no listed references which are not in the English language.

Date: *27 AUGUST 2001*

  
\_\_\_\_\_  
**Paul K. Legaard**  
Registration No. **38,534**

WOODCOCK WASHBURN KURTZ  
MACKIEWICZ & NORRIS LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439

**Form PTO-1449 Modified**Docket No.  
**UPAP-0287**Serial No.  
**09/486,625**List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)Applicant  
**Velpani Ayyavoo et al.**U.S. Department of Commerce  
Patent and Trademark OfficeFiling Date  
**September 13, 2000**Group  
**1643****OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	AA	Ayyavoo V, et al. "Development of genetic vaccines for pathogenic genes: construction of attenuated vif DNA immunization cassettes", <i>Aids</i> , 1997, 11, pp 1433-1444
	AB	Kim, J. J. et al. "Development of a multicomponent candidate vaccine for HIV-1", <i>Vaccine</i> , 1997, 15(8), pp 879-883
	AC	Miller, R. H. et al. "HIV accessory proteins as therapeutic targets", <i>Nature Medicine</i> , 1997, 3(4), pp 389-394

**EXAMINER****DATE CONSIDERED**

**Form PTO-1449 Modified**Docket No.  
**UPAP-0287**Serial No.  
**09/486,625**List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)Applicant  
**Velpandi Ayyavoo et al.**U.S. Department of Commerce  
Patent and Trademark OfficeFiling Date  
**September 13, 2000**Group  
**1643****U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation YES NO	
	AD	WO 95/05851	03/02/95	PCT		

**EXAMINER****DATE CONSIDERED**